Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Oct 19;326(15):1533-1535.
doi: 10.1001/jama.2021.15125.

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

Deborah Steensels  1 , Noella Pierlet  1 , Joris Penders  1 , Dieter Mesotten  1 , Line Heylen  1
Affiliations
Comparative Study

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

Deborah Steensels et al. JAMA. .

Abstract

This study compares the immune responses to the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines in health care workers in Belgium.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.
Figure.. Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination
Violin plots of circulating SARS-CoV-2 anti–spike protein receptor-binding domain antibodies in serum samples obtained from participants after they received 2 doses of an mRNA vaccine. Inside each violin plot, the geometric mean is depicted as a point. A, Difference between participants vaccinated with mRNA-1273 (Moderna) vs those with BNT162b2 (Pfizer-BioNTech). B, Difference according to previous SARS-CoV-2 infection and the type of mRNA vaccine. C, Difference according to age and the type of mRNA vaccine in previously uninfected participants. All comparisons were significant at P < .001 except previously infected participants (panel B), which was significant at P = .01.
See this image and copyright information in PMC

References

    1. Baden LR, El Sahly HM, Essink B, et al. ; COVE Study Group . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389 - DOI - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Voysey M, Costa Clemens SA, Madhi SA, et al. ; Oxford COVID Vaccine Trial Group . Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-891. doi:10.1016/S0140-6736(21)00432-3 - DOI - PMC - PubMed
    1. Khoury DS, Cromer D, Reynaldi A, et al. . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8 - DOI - PubMed
    1. Rubio-Acero R, Castelletti N, Fingerle V, et al. ; KoCo19 study team . In search of the SARS-CoV-2 protection correlate: head-to-head comparison of two quantitative S1 assays in pre-characterized oligo-/asymptomatic patients. Infect Dis Ther. 2021;10(3):1505-1518. doi:10.1007/s40121-021-00475-x - DOI - PMC - PubMed

Publication types